We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+6.84%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.79B
AUM Growth
-$153M
(-7.9%)
Cap. Flow
-$217M
Cap. Flow
% of AUM
-12.08%
Top 10 Holdings %
Top 10 Hldgs %
46.91%
Holding
72
New
23
Increased
11
Reduced
17
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$129M |
| 2 |
Pfizer
PFE
|
+$97.3M |
| 3 |
Bausch Health
BHC
|
+$87.4M |
| 4 |
Keysight
KEYS
|
+$66.8M |
| 5 |
Illumina
ILMN
|
+$63.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$96.7M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
+$95.4M |
| 3 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$73M |
| 4 |
Intuitive Surgical
ISRG
|
+$69.4M |
| 5 |
Danaher
DHR
|
+$68.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.97% |
| 2 | Technology | 3.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cardinal Health
CAH
$53.9B
| $31.1M | 1.73% |
+385,200
| New | +$30.4M |
|
27
Zimmer Biomet
ZBH
$18.2B
| $30M | 1.67% |
+272,332
| New | +$28.7M |
|
|
AMRI
28
DELISTED
Albany Molecular Research Inc
AMRI
| $26M | 1.45% |
1,600,000
+200,000
| +14% | +$3.67M |
|
|
ALXN
29
DELISTED
Alexion Pharmaceuticals
ALXN
| $23.5M | 1.31% |
127,100
-22,900
| -15% | -$4.24M |
|
30
Zoetis
ZTS
$32.4B
| $22.1M | 1.23% |
+512,500
| New | +$20.8M |
|
|
CELG
31
DELISTED
Celgene Corp
CELG
| $20.3M | 1.13% |
+181,600
| New | +$19.2M |
|
32
Brookdale Senior Living
BKD
$3.49B
| $20.3M | 1.13% |
553,500
+83,500
| +18% | +$2.83M |
|
|
ARAV
33
DELISTED
Aravive, Inc. Common Stock
ARAV
| $19.6M | 1.09% |
145,833
+20,833
| +17% | +$2.44M |
|
34
Teva Pharmaceuticals
TEVA
$40.8B
| $16.3M | 0.91% |
+284,000
| New | +$15.8M |
|
|
35
CALL
Pfizer
PFE
$143B
| $15.6M | 0.87% |
+527,000
| New | +$15.1M |
|
36
Pacira BioSciences
PCRX
$1.04B
| $11.1M | 0.62% |
+125,000
| New | +$11.8M |
|
37
Akebia Therapeutics
AKBA
$354M
| $9.84M | 0.55% |
845,254
-54,746
| -6% | -$785K |
|
38
Agilent Technologies
A
$39.1B
| $9.8M | 0.55% |
239,500
-1,228,400
| -84% | -$49.5M |
|
|
VAR
39
PUT
DELISTED
Varian Medical Systems, Inc.
VAR
| $8.65M | 0.48% |
+114,038
| New | +$8.49M |
|
|
DSCI
40
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $8.56M | 0.48% |
920,000
| – | – |
|
|
41
Danaher
DHR
$137B
| $4.5M | 0.25% |
78,111
-1,260,938
| -94% | -$68.4M |
|
42
Novavax
NVAX
$1.2B
| $3.85M | 0.21% |
32,489
+2,989
| +10% | +$312K |
|
|
INFI
43
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $3.78M | 0.21% |
223,712
-938,488
| -81% | -$13.7M |
|
|
ACGN
44
DELISTED
Aceragen Inc
ACGN
| $3.56M | 0.2% |
5,949
-307
| -5% | -$123K |
|
|
KYTH
45
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| $3.18M | 0.18% |
+91,600
| New | +$3.2M |
|
46
Celldex Therapeutics
CLDX
$2.99B
| $2.99M | 0.17% |
+10,907
| New | +$2.71M |
|
|
KERX
47
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $2.52M | 0.14% |
+178,300
| New | +$2.76M |
|
|
ELOS
48
DELISTED
Syneron Medical Ltd
ELOS
| $2.46M | 0.14% |
263,400
+34,600
| +15% | +$334K |
|
|
XOMA
49
DELISTED
Xoma
XOMA
| $1.62M | 0.09% |
22,500
+14,900
| +196% | +$1.28M |
|
|
ACHN
50
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
| $1.23M | 0.07% |
100,000
-400,000
| -80% | -$4.88M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2014 Portfolio in Review
As of Q4 2014, HealthCor Management held 72 positions worth $1.79B, down 7.9% from $1.95B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HealthCor Management withdrew a net $217M in Q4 2014, closing 20 positions and reducing 17 holdings. Its most notable exit was Veradigm Inc. Common Stock, an estimated $96.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 64% a quarter earlier, followed by Technology.
Against the trend, HealthCor Management opened a new position in Gilead Sciences worth $118M.
- HealthCor Management's largest Q4 2014 buy was Gilead Sciences: 1,250,000 shares worth $118M.
- HealthCor Management added most to Thermo Fisher Scientific in Q4 2014, an estimated $41.9M increase.
- HealthCor Management's biggest Q4 2014 reduction was Intuitive Surgical, cutting an estimated $69.4M.
- HealthCor Management fully exited Veradigm Inc. Common Stock in Q4 2014, selling an estimated $96.7M.
- HealthCor Management's ten largest holdings make up 47% of its $1.79B portfolio in Q4 2014.
- HealthCor Management opened 23 new positions and closed 20 in Q4 2014.
- HealthCor Management's portfolio value fell 7.9% quarter-over-quarter to $1.79B.
Based on HealthCor Management's 13F filing for Q4 2014, filed 17 Feb 2015.